CRT 2025

Panel Discussion | How Should We Proceed with Tricuspid Valve Interventions and When Should We Intervene?

Panel Moderator(s)

• 

  Sammy Elmariah, MD, MPH

  Associate Professor of Medicine
  University of California San Francisco
  San Francisco, California, United States

  Disclosure information not submitted.
• 

  Azeem Latib, MD

  Director, Interventional Cardiology & Structural Heart Interventions
  Montefiore Medical Center
  Scarsdale, New York, United States

  Disclosure(s): Boston Scientific, Metronic: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Molly Szerlip, MD

  Associate Medical Director, Education & Reserach and Regional Director, Sturctural Heart Progam
  Baylor Scott and White The Heart Hospital Baylor Plano
  Richardson, Texas, United States

  Disclosure(s): Abbott Vascular, Edwards, Medtronic, Boston Scientific: Advisory Board (Ongoing); Cardiovascular Innovations Foundation: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Edwards Lifesciences: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Scientific Advisory Board for AMA, ACC (BOT Member, SC Member CTR Program), SCAI (Women in Innovations Committee Member), JAMA Cardiology Associate Editor; Faculty CRF: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Panel Discussant(s)

• 

  Saif Anwaruddin, MD

  Associate Prof of Medicine/Director, Structural Heart Program
  Medical College Of Wisconsin
  Wauwatosa, Wisconsin, United States

  Disclosure(s): East End Medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Suzanne Arnold, MD

  Professor
  Saint Luke's Mid America Heart Institute

  Disclosure(s): No financial relationships to disclose
• 

  Steven F. Bolling, MD

  Professor of Cardiac Surgery
  University of Michigan Hospital
  Ann Arbor, Michigan, United States

  Disclosure information not submitted.
• 

  David J. Cohen, MD, FSCAI

  Director of Clinical and Outcomes Research
  Cardiovascular Research Foundation
  New York, New York, United States

  Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CathWorks: Grant/Research Support (Ongoing); Corvia Medical, Inc.: Grant/Research Support (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Medtronic, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Philips: Grant/Research Support (Ongoing); Zoll Medical: Grant/Research Support (Ongoing)
• 

  Raj Makkar, MD, FSCAI, FACC

  Vice President of Cardiovascular Innovation and Intervention
  Cedars-Sinai Medical Center
  Los Angeles, California, United States

  Disclosure information not submitted.
• 

  Georg Nickenig, MD

  Director Medical Hospital II
  University Hospital Bonn, Nordrhein-Westfalen, Germany

  Disclosure information not submitted.
• 

  Rishi Puri, MBBS PhD FRACP

  Staff Structural and Coronary Interventionalist
  Cleveland Clinic
  Cleveland Heights, Ohio, United States

  Disclosure information not submitted.
• 

  Paul Sorajja, MD

  Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital
  Allina Health Minneapolis Heart Institute
  Minneapolis, Minnesota, United States

  Disclosure(s): LAZA: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Pradeep Yadav, MD

  Director of Structural Interventions
  Piedmont Atlanta Hospital
  Atlanta, Georgia, United States

  Disclosure information not submitted.